KUALA LUMPUR, Sept 26 (Bernama) -- The International WELL Building Institute (IWBI) announced today the first participants in WELL Portfolio, a new streamlined pathway for WELL Certification of multiple new or existing buildings and tenant spaces in a single portfolio.
Released as part of the WELL v2 pilot, the latest iteration of the WELL Building Standard (WELL) is part of a suite of enhancements to WELL which addresses the growing demand across the building industry for a programme that helps owners, developers and tenants streamline and scale health and wellness upgrades in their real estate assets. The addition of an early-phase review process enabling projects to seek the WELL D&O designation introduced in WELL v2 allows portfolio projects to move through the certification process in a more streamlined and systematic fashion across their asset base. The WELL Portfolio Pathway encourages owners to treat achieving WELL as a journey and not a destination, and to make incremental improvements across their portfolios over time, a statement said. Tenants, developers and investors from Europe, North America, Australia and Asia have expressed interest in pursuing the WELL Portfolio Pathway, having already used WELL for individual buildings, and are now looking to bring the same value and evidence-based performance to their portfolios. IWBI is leading the global movement to transform buildings and communities in ways that help people thrive. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices and generally enhance -- not compromise -- our health and wellness. For more information, visit https://www.wellcertified.com. -- BERNAMA
0 Comments
KUALA LUMPUR, Sept 25 (Bernama) -- The Federal Aviation Agency (FAA) has granted approval for the maintenance intervals escalation of the CRJ700, CRJ900 and CRJ1000 aircraft.
The line maintenance interval (A-check) is extended to 800 flight hours and the heavy maintenance interval (C-check) to 8,000 flight hours, a statement today said. “We are thrilled that our operators are benefiting from our continuous improvement mindset as with this evolution, the CRJ Series operators can now take advantage of 14 per cent less maintenance days, meaning more days of revenue flying,” said Bombardier Commercial Aircraft CRJ Series programme head, Charles Comtois. The maintenance intervals have doubled since the launch of the CRJ aircraft family. The new maintenance intervals are applicable for new production deliveries as well as all CRJ700, CRJ900, and CRJ1000 aircraft in service. For more information, visit www.bombardier.com. -- BERNAMA KUALA LUMPUR, Sept 25 (Bernama) -- Toshiba Electronic Devices & Storage Corporation’s new four-channel power amplifier for car audio, the TCB503HQ, delivers strong resistance to power surges.
Higher reliability is able to be achieved because of Toshiba’s proven development capabilities in ICs for car audio. The product supports 6V operations suitable for vehicles equipped with idling reduction systems and helps suppress the popping sounds that occur when power voltage fluctuates. Other features include a built-in filter to improve resistance to extraneous high-frequency noise and to prevent the generation of abnormal noise even when there is high-frequency noise from mobile phone radio waves and adjustment of door mirrors. Sample shipments start today, said a statement, with mass production scheduled to begin in the first quarter of 2019. For more information, visit https://toshiba.semicon-storage.com -- BERNAMA SINGAPORE, Sept 28 (Bernama-BUSINESS WIRE) -- A.M. Best has assigned a Financial Strength Rating of B+ (Good) and a Long-Term Issuer Credit Rating of “bbb-” to Petrolimex Insurance Corporation (PJICO) (Vietnam). The outlook assigned to these Credit Ratings (ratings) is stable.
PJICO’s two largest shareholders are Vietnam National Petroleum Corporation (Petrolimex) (41% ownership) and Samsung Fire & Marine Insurance Co, Ltd. (20% ownership) (SFM). Petrolimex is the biggest domestic petro-oil distributor in Vietnam and one of the largest state-owned enterprises there. SFM is the leading non-life insurer in South Korea. The ratings reflect PJICO’s balance sheet strength, which A.M. Best categorizes as strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. PJICO’s risk-adjusted capitalization, as measured by Best’s Capital Adequacy Ratio (BCAR), is supported by a conservative and highly liquid investment portfolio, which is composed of mainly cash and bank deposits. Prospectively, A.M. Best expects PJICO’s BCAR ratios to remain supportive of its strong balance sheet assessment, despite being on a declining trend. PJICO was the fifth-largest player in Vietnam’s non-life market in 2017 with a 6.5% market share. The affiliation with Petrolimex has provided PJICO with access to favorable cargo business, which has contributed significantly to the company’s underwriting performance. In addition, PJICO is leveraging Petrolimex’s countrywide network of more than 2,500 petrol stations to distribute retail insurance products. An offsetting rating factor is a trend of reduced underwriting margins as a result of intensifying market competition in the motor and health segments. The company has achieved overall profitability for five years, but it has relied largely on the cargo business (10% of group premium written) and interest income to offset the weakening performance in other major lines of business. The company is well-positioned at the current rating. Negative rating actions could occur if the operating performance weakens materially. Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication. This press release relates to Credit Ratings that have been published on A.M. Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see A.M. Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and A.M. Best press releases, please view Guide for Media - Proper Use of Best’s Credit Ratings and A.M. Best Rating Action Press Releases. A.M. Best is a global rating agency and information provider with a unique focus on the insurance industry. Visit www.ambest.com for more information. Copyright © 2018 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on businesswire.com: https://www.businesswire.com/news/home/20180927005730/en/ Contact A.M. Best Tran Nhat Trung, +65 6303 5019 Financial Analyst [email protected] or Chi Yeung Lok, +65 6303 5016 Director, Analytics [email protected] or Christopher Sharkey, +1 908 439 2200, ext. 5159 Manager, Public Relations [email protected] or Jim Peavy, +1 908 439 2200, ext. 5644 Director, Public Relations [email protected] Source : A.M. Best SAN DIEGO, Sept 28 (Bernama-GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine® today announces Pharmaceuticals and Medical Devices Agency (PMDA) approval of the LeukoStrat CDx FLT3 Mutation Assay companion diagnostic.
As the first company to receive both FDA and PMDA approval for an acute myeloid leukemia (AML) companion diagnostic, Invivoscribe continues our mission for global standardization of diagnostic testing and expanding our global laboratory network. The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene. The globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to gilteritinib fumarate. Invivoscribe developed this companion diagnostic as an aid in identifying FLT3 mut+ AML patients eligible for treatment with gilteritinib fumarate (Xospata®). FLT3 somatic variants are among the most common driver mutations with the strongest effects on the overall survival in acute myeloid leukemia1. This companion diagnostic screened subjects for enrollment eligibility into the Phase 3 ADMIRAL study evaluating gilteritinib fumarate for the treatment of FLT3 mutation-positive (FLT3 mut+) relapsed or refractory AML adult patients. The LeukoStrat CDx FLT3 Mutation Assay is available as a commercial service offering from LabPMM GK in Japan to identify FLT3 mut+ AML patients for possible Xospata® treatment. Distributable LeukoStrat CDx FLT3 Mutation Assay Kits are expected to begin shipment from LabPMM GK, the Marketing Authorization Holder (MAH) in Japan, in late 2018. “Invivoscribe has long been committed to international standardization of molecular diagnostic tests. Test standardization is a critical part of precision medicine as it helps to refine treatments and accelerate drug approvals. Approval of our LeukoStrat CDx FLT3 Mutation Assay in Japan follows on the approval of the same test by the FDA in the US last year. These milestones represent a significant step towards standardized detection of one of the most important driver mutations in AML.”, said Jeffrey Miller, CSO & CEO of Invivoscribe. Invivoscribe is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics. LabPMM GK is an accredited subsidiary of Invivoscribe. For additional information please contact LabPMM GK at [email protected] or visit www.invivoscribe.com/clinical-services. 1) Papaemmanuil E, Gerstung M, Bullinger L, et al. N Engl J Med 2016; 374(23):2209-2221 SOURCE : Invivoscribe, Inc. |
Archives
April 2023
|